An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Status:	Recruiting
Conditions:	Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	2/2/2019
Start Date:	March 20, 2018
End Date:	December 19, 2021
Contact:	Recruiting sites have contact information. Please contact the sites directly. If there is no contact information
Email:	Clinical.Trials@bms.com
Phone:	please email:

A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers

The purpose of this study is to determine whether BMS-986299 both by itself and in
combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced
solid tumors. In addition, the ability of study drugs to stimulate an immune response against
cancer will be investigated.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histologically or cytologically confirmed advanced/metastatic solid tumor and
refractory to or intolerant of existing therapy(ies) known to provide clinical benefit
for the condition of the participant

- IO therapy resistant or insensitive tumors

- Have at least 2 tumor lesions accessible for biopsy

- Eastern Cooperative Oncology Group Performance Status of 0 or 1

Exclusion Criteria:

- Primary central nervous system malignancy

- Participants with other active malignancy requiring concurrent intervention

- Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

M.D. Anderson Cancer Center

Houston, Texas 77030

from

Houston, TX